Unresectable malignant pleural mesothelioma. 1st-line/monotherapy treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
Monotherapy in NSCLC 500 mg/m2 as IV infusion over 10 min on the 1sy days of each 21-day cycle. 500 mg/m2 IV infusion over 10 min on the 1st day of each 21-day cycle + cisplatin 75 mg/m2 infused approx 30 min after completion of Pemetrexed infusion on the 1st day of each 21-day cycle. Premedication regimen: Oral dexamethasone 4 mg bid prior to, on the day of, & the day after Pemetrexed administration to reduce incidence & severity of skin reactions. Vit supplementation: Oral folic acid or multivit containing folic acid 350-1,000 mcg daily to reduce toxicity.
Can suppress bone marrow function. Monitor for myelosuppression. Instruct patient to take folic acid & vit B12 to reduce treatment-related toxicity. Skin reactions in patients not pre-treated w/ corticosteroids. Not recommended in patients w/ CrCl <45 mL/min. Mild to moderate renal insufficiency. Severe dehydration when combined w/ cisplatin. Immunodepressed status. Concomitant use of live attenuated vaccines (except Yellow fever) is not recommended. Possibility of irreversible infertility in men. May affect ability to drive or operate machinery. Women of childbearing potential. Pregnancy & lactation.
Sign Out
